The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Use of NSAIDs in treating patients with arthritis
Open accessAbstract
Patients with rheumatic diseases, including rheumatoid arthritis and osteoarthritis, almost universally describe pain and stiffness as important contributors to reduced health-related quality of life. Of the treatment options available, NSAIDs are the most widely used agents for symptomatic treatment. NSAIDs are effective anti-inflammatory and analgesic drugs by virtue of their ability to inhibit biosynthesis of prostaglandins at the level of the cyclooxygenase enzyme. However, many of the adverse effects of NSAIDs are also related to inhibition of prostaglandin production, making their use problematic in some patient populations. For the clinician, understanding the biology of prostaglandin as it relates to gastrointestinal, renal, and cardiovascular physiology and the pharmacologic properties of specific NSAIDs is key to using these drugs safely. Of particular importance is the recognition of co-morbid conditions and concomitant drugs that may increase the risk of NSAIDs in particular patients. In patients with risk factors for NSAID toxicity, using the lowest dose of a drug with a short half-life only when it is needed is likely to be the safest treatment option. For those patients whose symptoms cannot be managed with intermittent treatment, using protective strategies is essential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cyclooxygenases: Structural, cellular, and molecular biology
Smith, W. L., DeWitt, D. L., & Garavito, R. M. (2000) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.69.1.145 · Cited by 2,925 · cited 4×
“COX-1 and COX-2 are bifunctional enzymes that mediate a COX reaction whereby arachidonate plus two molecules of oxygen are converted to the cyclic endoperoxide PGG2, followed by a hydroperoxidase reaction in which PGG2 undergoes a two-electron reduction to PGH2 [8].”
BackgroundInfluentialStructural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents
Kurumbail, R. G., Stevens, A. M., Gierse, J. K., McDonald, J. J., Stegeman, R. A., Pak, J. Y., Gildehaus, D., iyashiro, J. M., Penning, T. D., Seibert, K., et al. (1996) · Nature · doi:10.1038/384644a0 · Cited by 1,917
OARSI recommendations for the management of hip and knee osteoarthritis
Zhang, W., Nuki, G., Moskowitz, R. W., Abramson, S., Altman, R. D., Arden, N. K., Bierma-Zeinstra, S., Brandt, K. D., Croft, P., Doherty, M., et al. (2010) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2010.01.013 · Cited by 1,700
Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition
Simmons, D. L., Botting, R. M., & Hla, T. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.3.3 · Cited by 1,693
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
FitzGerald, G. A., & Patrono, C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450607 · Cited by 1,565
Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis
Trelle, S., Reichenbach, S., Wandel, S., Hildebrand, P., Tschannen, B., Villiger, P. M., Egger, M., & Juni, P. (2011) · BMJ · doi:10.1136/bmj.c7086 · Cited by 1,166
Kelley's Textbook of Rheumatology
(2013) · Elsevier eBooks · doi:10.1016/c2009-1-62542-9 · Cited by 1,101
Coxibs and Cardiovascular Disease
FitzGerald, G. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048288 · Cited by 899
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
Jüni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P. A., & Egger, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17514-4 · Cited by 846
Guidelines for Prevention of NSAID-Related Ulcer Complications
and the Practice Parameters Committee of the American College of Gastroenterology, Lanza, F. L., Chan, F. K. L., & Quigley, E. M. M. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.115 · Cited by 790
Page, J., & Henry, D. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.6.777 · Cited by 517
Topical NSAIDs for chronic musculoskeletal pain in adults
Derry, S., Conaghan, P., Da Silva, J. A. P., Wiffen, P. J., & Moore, R. A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007400.pub3 · Cited by 388
Solomon, S. D., Wittes, J., Finn, P. V., Fowler, R., Viner, J., Bertagnolli, M. M., Arber, N., Levin, B., Meinert, C. L., Martin, B., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.764530 · Cited by 367
Patrono, C., Patrignani, P., & Rodríguez, L. A. G. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13418 · Cited by 364
García Rodríguez, L. A., Tacconelli, S., & Patrignani, P. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.08.041 · Cited by 305
Basic biology and clinical application of specific cyclooxygenase-2 inhibitors
Crofford, L. J., Lipsky, P. E., Brooks, P., Abramson, S. B., Simon, L. S., & Van De Putte, L. B. A. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200001)43:1<4::aid-anr2>3.0.co;2-v · Cited by 296
Self-citationAcetaminophen, Aspirin, and Chronic Renal Failure
Fored, C. M., Ejerblad, E., Lindblad, P., Fryzek, J. P., Dickman, P. W., Signorello, L. B., Lipworth, L., Elinder, C.-G., Blot, W. J., McLaughlin, J. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010323 · Cited by 292
Yaksh, T. L., Dirig, D. M., Conway, C. M., Svensson, C., Luo, Z. D., & Isakson, P. C. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-16-05847.2001 · Cited by 270
Renal Effects of COX-2-Selective Inhibitors
Brater, D. C., Harris, C., Redfern, J. S., & Gertz, B. J. (2001) · American Journal of Nephrology · doi:10.1159/000046212 · Cited by 265
Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding
Massó González, E. L., Patrignani, P., Tacconelli, S., & Rodríguez, L. A. G. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27412 · Cited by 264
Pincus, T., Koch, G. G., Sokka, T., Lefkowith, J., Wolfe, F., Jordan, J. M., Luta, G., Callahan, L. F., Wang, X., Schwartz, T., et al. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200107)44:7<1587::aid-art282>3.0.co;2-x · Cited by 229
Initiation of Antihypertensive Treatment During Nonsteroidal Anti-inflammatory Drug Therapy
Gurwitz, J. H. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03520100043031 · Cited by 220
Nociception in cyclooxygenase isozyme-deficient mice
Ballou, L. R., Botting, R. M., Goorha, S., Zhang, J., & Vane, J. R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180319297 · Cited by 205
Ito, S., Okuda-Ashitaka, E., & Minami, T. (2001) · Neuroscience Research · doi:10.1016/s0168-0102(01)00289-9 · Cited by 198
Feenstra, J., Heerdink, E. R., Grobbee, D. E., & Stricker, B. H. C. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.3.265 · Cited by 194
Pharmacodynamic of cyclooxygenase inhibitors in humans
Capone, M. L., Tacconelli, S., Di Francesco, L., Sacchetti, A., Sciulli, M. G., & Patrignani, P. (2007) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2006.05.019 · Cited by 190
Keeble, J. E., & Moore, P. K. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704876 · Cited by 187
Kienzler, J., Gold, M. S., & Nollevaux, F. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009336234 · Cited by 156
Nonnarcotic Analgesic Use and the Risk of Hypertension in US Women
Dedier, J., Stampfer, M. J., Hankinson, S. E., Willett, W. C., Speizer, F. E., & Curhan, G. C. (2002) · Hypertension · doi:10.1161/01.hyp.0000035856.77718.da · Cited by 145
Analgesic Use and Renal Function in Men
Rexrode, K. M. (2001) · JAMA · doi:10.1001/jama.286.3.315 · Cited by 122
Anti-inflammatory agents and renal function☆, ☆☆
Brater, D. C. (2002) · Seminars in Arthritis and Rheumatism · doi:10.1053/sarh.2002.37216 · Cited by 118
Lanas, Á. (2009) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3181ad8cd3 · Cited by 102
Differential binding mode of diverse cyclooxygenase inhibitors
Llorens, O., Pérez, J. J., Palomer, A., & Mauleón, D. (2002) · Journal of Molecular Graphics and Modelling · doi:10.1016/s1093-3263(01)00135-8 · Cited by 84
Hauber, B., Arden, N. K., Mohamed, A. F., Johnson, F. R., Peloso, P. M. J., Watson, D. J., Mavros, P., Gammaitoni, A. R., Sen, S. S., & Taylor, S. D. (2012) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2012.11.007 · Cited by 81
Goldstein, J. L., Hochberg, M. C., Fort, J. G., Zhang, Y., Hwang, C., & Sostek, M. B. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04378.x · Cited by 80
Update on Cyclooxygenase-2 Inhibitors
Harris, R. C., & Breyer, M. D. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00890805 · Cited by 75
Mort, J. R., Aparasu, R. R., & Baer, R. K. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.9.1307 · Cited by 69
Colebatch, A. N., Marks, J. L., van der Heijde, D. M. F. M., & Edwards, C. J. (2012) · Journal of Rheumatology Supplement · doi:10.3899/jrheum.120345 · Cited by 64
Kunori, S., Matsumura, S., Okuda‐Ashitaka, E., Katano, T., Audoly, L., Urade, Y., & Ito, S. (2010) · Glia · doi:10.1002/glia.21090 · Cited by 61
Antiplatelet drug interactions
Mackenzie, I. S., Coughtrie, M. W. H., MacDonald, T. M., & Wei, L. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02299.x · Cited by 52
New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis☆, ☆☆
HOCHBERG, M. (2002) · Seminars in Arthritis and Rheumatism · doi:10.1053/sarh.2002.37215 · Cited by 51
Hinz, B., & Brune, K. (2007) · Springer eBooks · doi:10.1007/978-3-540-33823-9_3 · Cited by 50
Defining the Problem of Treating the Patient with Hypertension and Arthritis Pain
White, W. B. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.002 · Cited by 46
Non-Steroidal Anti-Inflammatory Drugs and Gastroprotection with Proton Pump Inhibitors
Gigante, A. P., & Tagarro, I. (2012) · Clinical Drug Investigation · doi:10.2165/11596670-000000000-00000 · Cited by 44
Capone, M. L., Tacconelli, S., Rodríguez, L. G., & Patrignani, P. (2010) · Pharmacological Reports · doi:10.1016/s1734-1140(10)70310-8 · Cited by 44
EXTENT OF RENAL EFFECT OF CYCLO‐OXYGENASE‐2‐SELECTIVE INHIBITORS IS PHARMACOKINETIC DEPENDENT
Harirforoosh, S., Aghazadeh‐Habashi, A., & Jamali, F. (2006) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2006.04464.x · Cited by 43
The choreography of cyclooxygenases in the kidney
FitzGerald, G. A. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0216044 · Cited by 30
Friedewald, V. E., BENNETT, J. S., Christo, J. P., Pool, J. L., Scheiman, J. M., Simon, L. S., Strand, V., White, W. B., Williams, G. W., & Roberts, W. C. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.04.006 · Cited by 26
Bello, A. E. (2012) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x12444710 · Cited by 15
Prostanoid Biology and Its Therapeutic Targeting
Crofford, L. J. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4377-1738-9.00059-1 · Cited by 6
Self-citationGravellese (2000) · Pure Amsterdam UMC · doi:10.1002/1529-0131(200002)43:2 · Cited by 2
Cited by
Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective
Bindu, S., Mazumder, S., & Bandyopadhyay, U. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114147 · Cited by 1,920
Management of Rheumatoid Arthritis: An Overview
Radu, A.-F., & Bungau, S. G. (2021) · Cells · doi:10.3390/cells10112857 · Cited by 1,089
Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis
Lin, Y.-J., Anzaghe, M., & Schülke, S. (2020) · Cells · doi:10.3390/cells9040880 · Cited by 932
Ward, M. M., Deodhar, A., Akl, E. A., Lui, A., Ermann, J., Gensler, L. S., Smith, J. A., Borenstein, D., Hiratzka, J., Weiss, P. F., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39298 · Cited by 548
Signaling pathways in rheumatoid arthritis: implications for targeted therapy
Ding, Q., Hu, W., Wang, R., Yang, Q., Zhu, M., Li, M., Cai, J., Rose, P., Mao, J., & Zhu, Y. Z. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01331-9 · Cited by 478
Metadata
- Authors
- Crofford, L. J.
- Venue
- Arthritis Research & Therapy
- Published
- 2013-07
- Volume
- 15
- Issue
- S3
- Pages
- S2-S2
- ISSN
- 1478-6354 (ISSN-L)
- OpenAlex
- W1907909084
- Cited by
- 650
- References
- 51
- FWCI
- 12.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.